

Interface and Formulary Update - Issue 40

January 2026

Key messages from January 2026 TAG meeting - (ratified by Medicines Optimisation Programme Board)

Formulary Review – Pill in a Pocket - Flecainide

- Treatment for Paroxysmal Atrial Fibrillation
- Patient only takes when they experience an attack or episode
- Members confirmed that this practice is common and generally accepted by cardiologists, with no significant pushback from GP
- **Amber Initiate**

Formulary Review - Sparsentan for treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ≥ 0.75 g/g) as per [TA1074](#)

- There is a limited patient population. To be reviewed if use expands.
- **RED - Restricted Use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care**

Formulary Review – EURneffy® for emergency treatment of severe allergic reactions due to insect stings or bites, food, medicinal products and other allergens, and idiopathic or exercise-induced anaphylaxis, in adults and children ≥ 30 kg

- Adrenaline nasal spray which offers an alternative to current adrenaline auto-injector formulary options
- Useful for needle-phobic patients who meet criteria for use
- **BLACK – Not Commissioned. No prescribing in primary or secondary care recommendation** pending outcome of regional work by PAC

Pathway Review – Migraine routine update

- Use of topiramate in pregnancy is contra-indicated for migraine prophylaxis

Updates from Prescribing Formulary Group

Dexamethasone preservative-free eye drops – 0.3ml

- Replace 0.5ml generic requests with new 0.3ml preparation
- Keep 0.4ml branded preparation on formulary as additional option in case of sensitivities to excipients or supply issues

Vizilatan Duo 50 micrograms/ml + 5 mg/ml eye drops, preservative-free (latanoprost/timolol) – multi-dose eye drop

- **Amber Advice** - second line for patients who are intolerant / allergy to preservatives

Eroxon Gel for use in erectile dysfunction

- Available OTC. High cost on FP10
- Limited evidence. **BLACK - Not for NHS prescribing**

LoFric Elle Intermittent Catheters

- Non-formulary product - **BLUE** classification in interim pending full review

Epilepsy formulary review

- Existing arrangements reviewed, updated and formalised so that Netformulary section can go live

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

| | |
|-----------------|--|
| RED | TA1106 – November 2025 - Cabotegravir (Apretude®) for preventing HIV-1 in adults and young people (Commissioned by local authorities) |
| | TA1109 – November 2025 - Darolutamide (Nubeqa®) with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer |
| | TA1110 – November 2025 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer Replaces TA721 |
| | TA1113 – December 2025 - Glofitamab (Columvi®) with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma |
| | TA1114 – December 2025 - Talquetamab (Talvey®) for treating relapsed and refractory multiple myeloma after 3 or more treatments |
| | TA1115 – December 2025 - Vutrisiran (Amvuttra®) for treating transthyretin amyloidosis with cardiomyopathy |
| | TA1116 – December 2025 - Obecabtagene autoleucl (obe-cel; Aucatzyl®) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
| BLACK | TA1108 – November 2025 - Cemiplimab (Libtayo®) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer |
| | TA1111 – November 2025 - Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) |
| | TA1112 – November 2025 - Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) |
| NICE - Approved | TA1107 – November 2025 - Delgocitinib (Anzupgo®) for treating moderate to severe chronic hand eczema |

Useful Information

| | |
|-----------------------------------|--|
| Next TAG meeting | Wednesday 4th March 2026 |
| Deadline for agenda items | Tuesday 24th February 2026 |
| Netformulary | Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk) |
| Knowledge NoW – MO Team pages | Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk) |
| TAG Guidance | Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk) |
| Shared Care Agreements | Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk) |
| Pathways and Prescribing Guidance | Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk) |
| Practice Support | Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk) |
| Useful Links | Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk) |

- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates
- If you have any interface or formulary queries, please send to the inbox - nwcb.medsqueries@nhs.net